New Haven drug developer Rib-X Pharmaceuticals has raised another $20 million to fund ongoing safety and preclinical studies of its antibiotics to treat skin and tissue ailments caused by bacteria resistant to conventional treatments.
Rib-X’s current investor, Warburg Pincus LLC, led the latest round of equity financing. The Wall Street investment firm also owns a stake in Waterbury regional bank Webster Financial Corp.
Connecticut Innovations Inc., the state’s quasi-public technology investment arm, has a stake in Rib-X.
Rib-X CEO Mark Leuchtenberger says one of the biopharma’s drugs, delafloxacin, is scheduled to enter a Phase 2b study early this year, a prelude to clinical testing.
Founded in 2001, Rib-X has raised more than $148 million in equity and debt financing to refine its products.
